Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis

• Published in: Nature reviews. Rheumatology 2024-10, Vol.20 (10), p.601-613
• Main Authors: Holers, V. Michael, Demoruelle, Kristen M., Buckner, Jane H., James, Eddie A., Firestein, Gary S., Robinson, William H., Steere, Allen C., Zhang, Fan, Norris, Jill M., Kuhn, Kristine A., Deane, Kevin D.
• Format: Article
• Language: English
• Subjects: 692/4023/1670/498; 692/420/2780; 692/499; Animal models; Animals; Anti-Citrullinated Protein Antibodies - immunology; Arthritis, Rheumatoid - immunology; Autoantibodies; Autoantibodies - immunology; Autoimmune diseases; Cell culture; Citrulline; Dysbacteriosis; Helper cells; Humans; Hypotheses; Inflammation; Lymphocytes T; Medicine; Medicine & Public Health; Microbiota; Microorganisms; Mucosal immunity; Mucous Membrane - immunology; Mucous Membrane - pathology; Precision medicine; Review Article; Rheumatoid arthritis; Rheumatology; Th17 Cells - immunology
• ISSN: 1759-4790; 1759-4804; 1759-4804
• DOI: 10.1038/s41584-024-01154-0

Rheumatoid arthritis (RA) is a potentially devastating autoimmune disease. The great majority of patients with RA are seropositive for anti-citrullinated protein antibodies (ACPAs), rheumatoid factors, or other autoantibodies. The onset of clinically apparent inflammatory arthritis meeting classification criteria (clinical RA) is preceded by ACPA seropositivity for an average of 3–5 years, a period that is designated as ‘at-risk’ of RA for ACPA-positive individuals who do not display signs of arthritis, or ‘pre-RA’ for individuals who are known to have progressed to developing clinical RA. Prior studies of individuals at-risk of RA have associated pulmonary mucosal inflammation with local production of ACPAs and rheumatoid factors, leading to development of the ‘mucosal origins hypothesis’. Recent work now suggests the presence of multiple distinct mucosal site-specific mechanisms that drive RA evolution. Indicatively, subsets of individuals at-risk of RA and patients with RA harbour a faecal bacterial strain that has exhibited arthritogenic activity in animal models and that favours T helper 17 (T H 17) cell responses in patients. Periodontal inflammation and oral microbiota have also been suggested to promote the development of arthritis through breaches in the mucosal barrier. Herein, we argue that mucosal sites and their associated microbial strains can contribute to RA evolution via distinct pathogenic mechanisms, which can be considered causal mucosal endotypes. Future therapies instituted for prevention in the at-risk period, or, perhaps, during clinical RA as therapeutics for active arthritis, will possibly have to address these individual mechanisms as part of precision medicine approaches. Holers and colleagues review current data linking immune mechanisms and dysbiosis at distinct mucosal sites to risk of rheumatoid arthritis (RA). Their newly introduced causal mucosal endotypes hypothesis suggests that lung-, gut-, or oral-associated endotypes might drive the pathogenesis and progression of RA, and highlights associated research directions towards preventive and therapeutic strategies in RA. Key points The onset of seropositive rheumatoid arthritis (RA) is typically preceded by the presence of RA-related autoantibodies (ACPAs, rheumatoid factors, AMPAs) in the peripheral blood for 3–5 years prior to the onset of symptoms and histologically or imaging-identified joint inflammation. The period of time prior to clinical RA onset can be designated